• Explore /
  • Poster
  • / Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Abstract Poster

Authors

null

Shukui Qin

Cancer Center of Jinling Hospital, Nanjing Chinese Medicine University, Nanjing, China

Shukui Qin , Zhendong Chen , Weijia Fang , Zhenggang Ren , Ruocai Xu , Baek-Yeol Ryoo , Zhiqiang Meng , Yuxian Bai , Xiaoming Chen , Xiufeng Liu , Juxiang Xiao , Gwo Fuang Ho , Yimin Mao , Xing Ye , Jieer Ying , Jianfeng Li , Wen Yan Zhong , Yu Zhou , Abby B. Siegel , Chunyi Hao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03062358

DOI

10.1200/JCO.2022.40.4_suppl.383

Abstract #

383

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Shukui Qin

First Author: Richard S. Finn

First Author: Masatoshi Kudo

First Author: Richard S. Finn